Trastuzumab and Pertuzumab have been utilized as successful antibodies disrupting oncogenic signaling pathways by binding to HER2 (Human Epidermal growth factor Receptor 2) protein overexpressed on cancer cells [11]. The gene discussed is ERBB2; the disease is cancer.